澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PROTEOMICS INTERNATIONAL LAB

0.135

-0.005-3.57%

成交量：8.23萬

成交額：1.13萬

市值：2,229.07萬

市盈率：-2.59

高：0.145

開：0.140

低：0.135

收：0.140

52周最高：0.860

52周最低：0.098

股本：1.65億

流通股本：1.22億

量比：1.19

換手率：0.07%

股息：- -

股息率：- -

每股收益(TTM):-0.052

每股收益(LYR):-0.064

淨資產收益率：-92.99%

總資產收益率：-46.46%

市淨率：3.84

市盈率(LYR):-2.12

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股+1.18%

資金流向

資金流入：

資金流出：

新聞資訊

Proteomics International Laboratories — 本財務期間未支付、建議或宣派任何股息

Proteomics International Laboratories 與 Healius 簽署 Promarker 產品組合全國分銷協議

PROTEOMICS INTERNATIONAL LAB獲美國專利授予，革新子宮內膜異位症診斷檢測

Proteomics International Laboratories宣佈重組、高管任命及董事會變動

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/PIQ.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PIQ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PIQ.AU\",,,,,undefined,":{"symbol":"PIQ.AU","market":"AU","secType":"STK","nameCN":"PROTEOMICS INTERNATIONAL LAB","latestPrice":0.135,"timestamp":1789452720000,"preClose":0.14,"halted":0,"volume":82277,"delay":0,"changeRate":-0.03571428571428574,"nameEN":"PROTEOMICS INTERNATIONAL LAB","floatShares":121549097,"shares":165116433,"eps":-0.0521,"marketStatus":"未開盤","change":-0.005,"latestTime":"09-15 16:12:00 AEST","open":0.14,"high":0.145,"low":0.135,"amount":11277,"amplitude":0.071429,"askPrice":0.145,"askSize":83525,"bidPrice":0.125,"bidSize":15301,"shortable":3,"etf":0,"ttmEps":-0.0521,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.14,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":1.194518,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PIQ.AU","preClose":0.14,"auctionPrice":0.135,"auctionVolume":61989,"auction":3,"marketStatus":"盘后竞价","timestamp":1789452369359}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PIQ.AU\",,,,,undefined,":{"symbol":"PIQ.AU","floatShares":121549097,"roa":"-46.46%","roe":"-92.99%","lyrEps":-0.063752,"volumeRatio":1.194518,"shares":165116433,"dividePrice":0,"high":0.145,"amplitude":0.071429,"preClose":0.14,"low":0.135,"week52Low":0.098,"pbRate":"3.84","psRate":"6.61","week52High":0.86,"institutionHeld":0,"latestPrice":0.135,"committee":-0.690345,"eps":-0.0521,"divideRate":0,"volume":82277,"delay":0,"ttmEps":-0.0521,"open":0.14,"prevYearClose":0.655,"prevWeekClose":0.14,"prevMonthClose":0.15,"prevQuarterClose":0.115,"fiveDayClose":0.145,"twentyDayClose":0.155,"sixtyDayClose":0.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PIQ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PIQ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PIQ.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151806519","title":"Proteomics International Laboratories — 本財務期間未支付、建議或宣派任何股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1151806519","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151806519?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 14:42","pubTimestamp":1788158524,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories——在当前财务期间，公司既未支付、亦未建议或宣派任何股息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PIQ.AU","BK7048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191921589","title":"Proteomics International Laboratories 與 Healius 簽署 Promarker 產品組合全國分銷協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1191921589","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191921589?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 06:31","pubTimestamp":1784673073,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories 已与 Healius 就其 Promarker 产品组合签署了一份全国分销协议。此举旨在扩大其创新诊断解决方案的市场覆盖范围，通过 Healius 广泛的网络，将 Promarker 产品带给更广泛的医疗专业人士和患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7048","PIQ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166630655","title":"PROTEOMICS INTERNATIONAL LAB獲美國專利授予，革新子宮內膜異位症診斷檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=1166630655","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166630655?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 08:12","pubTimestamp":1783469559,"startTime":"0","endTime":"0","summary":"PROTEOMICS INTERNATIONAL LAB成功获得一项美国专利授权，该专利涉及其在子宫内膜异位症领域的一项创新诊断检测技术。这一进展标志着公司在生物标志物发现和诊断解决方案方面的专业能力获得了重要认可，有望为其在医疗诊断市场的布局提供新的知识产权保护与竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","PIQ.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142422629","title":"Proteomics International Laboratories宣佈重組、高管任命及董事會變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1142422629","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142422629?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 09:45","pubTimestamp":1776390315,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories有限公司公布重大运营调整，包括组织架构重组、高层人事任命及董事会更新。\n公司已正式任命Tim Luscombe担任首席财务官，这一关键人事变动将强化其财务管理团队。与此同时，为提升运营效率，公司决定削减25%的岗位编制。此项精简措施预计将实现每年超过100万澳元的常态化成本节约。\n此次人员调整是公司整体运营重组计划的重要组成部分。Proteomics International Laboratories表示，通过重构业务架构，旨在优化资源配置，提升长期竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7048","PIQ.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PIQ.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.011805}]}}